Management of hepatitis C in liver transplant recipients. (Q36392142)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16468953%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

review article

1 reference

title

Management of hepatitis C in liver transplant recipients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16468953%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

language of work or name

English

0 references

publication date

1 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16468953%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Transplantation

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16468953%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16468953%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16468953%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

449-458

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16468953%20AND%20SRC:MED&resulttype=core&format=json

The association between hepatitis C infection and survival after orthotopic liver transplantation

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Validation and refinement of survival models for liver retransplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Retransplantation for recurrent hepatitis C: The argument against

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Donor age influences 10-year liver graft histology independently of hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Predictors of patient and graft survival following liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

A longitudinal analysis of hepatitis C virus replication following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Outcomes of acute rejection after interferon therapy in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Treatment of HCV infection in patients with advanced cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Preemptive therapy for hepatitis C virus after living-donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Treatment of recurrent hepatitis C in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X

Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2005.01202.X